Matinas BioPharma gets NYSE American noncompliance notice over $1.8 million stockholders’ equity - MTNB News | RalliesMatinas BioPharma gets NYSE American noncompliance notice over $1.8 million stockholders’ equity
M
MTNB• NYSE American notice over stockholders’ equity
- Matinas BioPharma received an NYSE American notice citing non-compliance with continued listing standards tied to minimum stockholders’ equity.
- Stockholders’ equity stood at $1.8 million as of June 30, 2026, below the $2 million threshold under Section 1003(a)(i).
- NYSE American accepted a remediation plan, granting a compliance window through Oct. 2, 2027.
- Failure to regain compliance or meet plan milestones by the deadline could trigger delisting proceedings, subject to appeal rights.
- Shares remain listed during the plan period, with a .BC indicator attached to the ticker until compliance is restored.
MATW
•
